Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson's disease

BMC Neuroscience

Volumn 15, Issue , 2014, Pages

  Kadoguchi, Naoto ^a   Okabe, Shinji ^a   Yamamura, Yukio ^a   Shono, Misaki ^a   Fukano, Tatsuya ^a   Tanabe, Akie ^a   Yokoyama, Hironori ^a   Kasahara, Jiro ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine (MPTP); Dopamine; Mirtazapine; Noradrenergic and specific serotonergic antidepressant (NaSSA); Parkinson's disease; Serotonin (5 hydroxytryptamine, 5 HT)

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; CLONIDINE; DOPAMINE; DOPAMINE TRANSPORTER; HOMOVANILLIC ACID; MIRTAZAPINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PRAZOSIN; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2; MIANSERIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INCLINED BEAM WALKING TEST; INFANT; MALE; MOTOR DYSFUNCTION; MOUSE; MOUSE MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PROTEIN EXPRESSION; ROTAROD TEST; TURNOVER TIME; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; C57BL MOUSE; DRUG EFFECTS; FEASIBILITY STUDY; MPTP POISONING; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BRAIN; DISEASE MODELS, ANIMAL; FEASIBILITY STUDIES; MALE; MIANSERIN; MICE; MICE, INBRED C57BL; MPTP POISONING; TREATMENT OUTCOME;

EID: 84902912763     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-15-79     Document Type: Article

References (55)

1. Samii A, Nutt JG, Ransom B. Parkinson's disease. Lancet 2004, 363:1783-1793.
2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973, 20:415-455.
3. Agid Y. Parkinson's disease: pathophysiology. Lancet 1991, 337:1321-1324.
4. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. J Neurol 2002, 58:11-17.
5. Jain L, Benko R, Safranek S. Clinical inquiry. Which drugs work best for early Parkinson's disease?. J Fam Pract 2012, 61:106-108.
6. Rascol O, Fabre N. Dyskinesia: L{small}-dopa-induced and tardive dyskinesia. Clin Neuropharmacol 2001, 24:313-323.
7. Mathur BN, Lovinger DM. Serotonergic action on dorsal striatal function. Parkinsonism Relat Disord 2012, 18(Suppl 1):129-131.
8. Cheshire PA, Williams DR. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease. J Clin Neurosci 2012, 19:343-348.
9. Prinssen EP, Colpaert FC, Koek W. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 2002, 453:217-221.
10. Neal-Beliveau BS, Joyce JN, Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 2003, 265:207-217.
11. Ohno Y. Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease. CNS Neurosci Ther 2011, 17:58-65.
12. Holm KJ, Markham A. Mirtazapine: a review of its use in major depression. Drugs 1999, 57:607-631.
13. De Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 1996, 10(Suppl 4):19-23.
14. De Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996, 57(Suppl 4):19-25.
15. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995, 56:519-525.
16. van Moffaert M, de Wilde J, Vereecken A, Dierick M, Evrard JL, Wilmotte J, Mendlewicz J. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995, 10:3-9.
17. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998, 51:267-285.
18. Amini H, Aghayan S, Jalili SA, Akhondzadeh S, Yahyazadeh O, Pakravan-Nejad M. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial. J Clin Pharm Ther 2005, 30:133-138.
19. Høyberg OJ, Maragakis B, Mullin J, Norum D, Stordall E, Ekdahl P, Ose E, Moksnes KM, Sennef C. A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand 1996, 93:184-190.
20. Nakayama K, Sakurai T, Katsu H. Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain Res Bull 2004, 63:237-241.
21. Gordon PH, Pullman SL, Louis ED, Frucht SJ, Fahn S. Mirtazapine in Parkinsonian tremor. Parkinsonism Relat Disord 2002, 9:125-126.
22. Fox SH. Non-dopaminergic treatments for motor control in Parkinson's disease. Drugs 2013, 73:1405-1415.
23. Kasahara J, Choudhury ME, Yokoyama H, Kadoguchi N, Nomoto M. Neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced animal models for Parkinson's disease. Animal Models for The Study of Human Disease 2013, 633-650. London: Academic Press, Conn PM.
24. Yokoyama H, Kuroiwa H, Kasahara J, Araki T. Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced mouse model of Parkinson's disease. Acta Neurobiol Exp 2011, 71:269-280.
25. Yokoyama H, Yano R, Kuroiwa H, Tsukada T, Uchida H, Kato H, Kasahara J, Araki T. Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice. Metab Brain Dis 2010, 25:135-143.
26. Yabe H, Choudhury ME, Kubo M, Nishikawa N, Nagai M, Nomoto M. Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. J Pharmacol Sci 2009, 110:64-68.
27. Grenhoff J, Svensson TH. Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. Eur J Pharmacol 1993, 233:79-84.
28. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996, 153:466-476.
29. Blier P. Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response. J Psychiatry Neurosci 2001, 26(Suppl):3-10.
30. Blandini F, Armentero MT. Animal models of Parkinson's disease. FEBS J 2012, 279:1156-1166.
31. Rose S, Nomoto M, Kelly E, Kilpatrick G, Jenner P, Marsden CD. Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP. Neurosci Lett 1989, 101:305-310.
32. Gainetdinov RR, Caron MG. Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol 2003, 43:261-284.
33. Leviel V. Dopamine release mediated by the dopamine transporter, facts and consequences. J Neurochem 2011, 118:475-489.
34. Dazzi L, Spiga F, Pira L, Ladu S, Vacca G, Rivano A, Jentsch JD, Biggio G. Inhibition of stress- or anxiogenic-drug-induced increases in dopamine release in the rat prefrontal cortex by long-term treatment with antidepressant drugs. J Neurochem 2001, 76:1212-1220.
35. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001, 7:249-264.
36. Di Giovanni G, Esposito E, Di Matteo V. Role of serotonin in central dopamine dysfunction. CNS Neurosci Ther 2010, 16:179-194.
37. Sharp T, Boothman L, Raley J, Quérée P. Important messages in the 'post': recent discoveries in 5-HT neurone feedback control. Trends Pharmacol Sci 2007, 28:629-636.
38. Ferguson MC, Nayyar T, Deutch AY, Ansah TA. 5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease. Neuropharmacology 2010, 59:31-36.
39. Mignon L, Wolf WA. Postsynaptic 5-HT1A receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology 2002, 163:85-94.
40. Ishibashi T, Ohno Y. Antiparkinsonian actions of a selective 5-HT1A agonist, tandospirone, in rats. Biog Amines 2004, 8:329-338.
41. Dupre KB, Eskow KL, Barnum CJ, Bishop C. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induce dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 2008, 55:1321-1328.
42. Shimizu S, Tatara A, Imaki J, Ohno Y. Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders. Prog Neuro-Psychopharmacol Biol Psychiat 2010, 34:877-881.
43. El Mansari M, Guiard BP, Chernoloz O, Ghanbari R, Katz N, Blier P. Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther 2010, 16:e1-17.
44. Ogawa N, Asanuma M, Miyazaki I, Diaz-Corrales F, Miyoshi K. L{small}-DOPA treatment from the viewpoint of neuroprotection: Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease. J Neurol 2005, 252(Suppl 4):iv23-iv31.
45. Ahlskog JE, Munenter MD. Frequency of levodoparelated dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16:448-458.
46. Inden M, Abe M, Minamino H, Takata K, Yoshimoto K, Tooyama I, Kitamura Y. Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on L{small}-DOPA-induced rotational behavior in a hemiparkinsonian rat model. J Pharmacol Sci 2012, 119:10-19.
47. Johnston TH, Fox SH, Piggott MJ, Savola JM, Brotchie JM. The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. Mov Disord 2012, 25:2084-2093.
48. Costa FH, Rosso AL, Maultasch H, Nicaretta DH, Vincent MB. Depression in Parkinson's disease: diagnosis and treatment. Arq Neuropsiquiatr 2012, 70:617-620.
49. Perez-Lloret S, Rascol O. Parkinson disease: Serotonin reuptake inhibitors for depression in PD. Nat Rev Neurol 2012, 8:365-366.
50. Goodnick PJ, Hernandez M. Treatment of depression in comorbid medical illness. Expert Opin Pharmacother 2000, 1:1367-1384.
51. Kadoguchi N, Umeda M, Kato H, Araki T. Proteasome Inhibitor Does Not Enhance MPTP Neurotoxicity in Mice. Cell Mol Neurobiol 2008, 28:971-979.
52. Allbutt HN, Henderson JM. Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson's disease. J Neurosci Methods 2007, 159:195-202.
53. Araki T, Mikami T, Tanji H, Matsubara M, Imai Y, Mizugaki M, Itoyama Y. Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse. Eur J Pharm Sci 2001, 12:231-238.
54. Kurosaki R, Muramatsu Y, Kato H, Araki T. Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson's disease. Pharmacol Biochem Behav 2004, 78:143-153.
55. Takagi S, Hayakawa N, Kimoto H, Kato H, Araki T. Damage of oligodendrocytes in the striatum after MPTP neurotoxicity in mice. J Neural Transm 2007, 114:1553-1557.